Parse Biosciences Partners with Taiwan-based Prisma Biotech to Extend Reach in Asia

August 08, 2024,Seattle, United States : Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Taipei-based Prisma Biotech to broaden Parse’s reach in Taiwan and across Asia-Pacific.

“Biotech, pharma, and academic researchers across Asia are boosting demand for Parse’s Evercode single cell sequencing solutions in the region as they discover their scalability and simplicity,” noted Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. “We’re excited to empower them to easily take advantage of Parse’s single cell sequencing technology through our partnership with Prisma.”

The company’s agreement with Prisma Biotech will give a greater number of Asian researchers full access to Parse’s single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Select, CRISPR Detect, and the Parse Biosciences data analysis solution, Trailmaker. The agreement is a continuation of Parse’s ongoing market penetration in Asia, including South Korea, Singapore, and India, as well as in key international markets such as North America, Europe, Australia, Israel, and New Zealand.

“Single cell sequencing products are in high demand, and Parse’s Evercode technology is extremely compelling because of its scalability and ease of use,” noted Prisma Biotech CEO Kevin Tseng. “Our partnership with Parse will bring single cell sequencing to a wide range of researchers in Taiwan and the larger Asia-Pacific region, and we’re excited to support scientific discoveries the tools enable.”